A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS

B E Sands,V Jairath,K A Traxler,B Feagan,J Jones,S Schreiber,A Armuzzi,N Morris,X Li,T H Gibble

doi:10.1093/jcag/gwac036.031

A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS

B E Sands, V Jairath + Show 8 more

Open Access

PDF Available

https://doi.org/10.1093/jcag/gwac036.031

Copy DOI

Export

Save

Cite

Journal: Journal of the Canadian Association of Gastroenterology	Publication Date: Mar 7, 2023
Citations: 1	License type: CC BY 4.0

Affiliation: Icahn School of Medicine at Mount Sinai, Western University, Dalhousie University, University Hospital Schleswig-Holstein, IRCCS Humanitas Research Hospital, Eli Lilly (United States)

#Inflammatory Bowel Disease Questionnaire #Inflammatory Bowel Disease Questionnaire Scores #Total Inflammatory Bowel Disease Questionnaire Score #Meaningful Improvement In Quality Of Life #Proportions Of Pts #Total Score #Minimal Clinically Important Difference #Baseline #Common Risk Difference #Baseline Corticosteroid Use

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of the Canadian Association of Gastroenterology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS